Neurological Manifestations of IgG4-related Disease: To Wait or to Mitigate?

Document Type

Conference Proceeding - Restricted Access

Publication Date

5-8-2026

Abstract

Immunoglobulin G4-related disease (IgG4-RD) is a multi-organ, relapsing fibroinflammatory disorder that can rarely involve the central nervous system (CNS), especially neurology predominant IgG4-RD is not well described in literature. It manifests as hypertrophic pachymeningitis, hypo-physitis, and cranial neuropathies. MITIGATE Trial studied Inebilizumab's (Uplizna) efficacy for treatment of IgG4-RD and was recently approved by the Food and Drug Administration (FDA). Since then, literature is scarce for Uplizna been used to treat IgG4-RD. Therefore, our case series is a novel study describing the use and success of this medication in a patient in addition to other manifestations of IgG4-RD.

We managed three patients with histo-pathological confirmation of neurologically predominant IgG4-RD seen in the Neuroimmunology Clinic. Retrospective extraction of data from electronic medical records included demographics, symptomatology, neuroimaging, workup, histopathology, treatment regimens, and clinical outcomes. A comprehensive literature review was performed through PubMed, Embase, Scopus and Cochrane using keywords reporting CNS presentations and therapeutic outcomes with IgG4-RD. Data synthesis was qualitative due to heterogeneity among studies and limited sample size.

Patient 1 was a 64-year-old female presenting with monocular blurry vision, pachymeningeal enhancement and subdural hematoma. Biopsy demonstrated lymphoplasmacytic inflammation with IgG4-positive plasma cells. The patient was started on Inebilizumab after steroids and underwent surgical resection Patient 2 was a 61-year-old male with recurrent pituitary masses due to IgG4-RD and multiple cranial neuropathies. Surgical resection and maintenance of low-dose corticosteroids achieved control. Patient 3 was a 23-year-old female with a rapidly progressive pituitary mass causing panhypopituitarism. Histopathology demonstrated granulomatous inflammation with >100 IgG4-positive plasma cells/hpf and underwent surgery. Across cases, neuroimaging commonly revealed sellar/suprasellar or pachymeningeal involvement, and pathology confirmed dense IgG4+ plasma cell infiltrates. Literature review corroborated that early recognition and immunosuppression improves prognosis, though standardized treatment guidelines remain lacking.

Recognition of IgG4-RD requires high clinical suspicion and histopathologic confirmation. Corticosteroids remain the cornerstone of management but the emergence of Inebilizuamb poses a treatment dilemma in neurological-confined IgG4 since now there is an effective FDA approved drug available.

Comments

2026 Research Day Corewell Health West, Grand Rapids, MI, May 8, 2026. Abstract 1934

This document is currently not available here.

Share

COinS